Form 4: BioAtla CEO Jay Short Reports Tax-Related Share Withholding Following RSU Vesting

BioAtla, Inc.'s Chief Executive Officer and 10% owner, Jay M. Short, PhD, reported the withholding of 6,347 shares of common stock by the issuer to cover tax obligations related to the vesting of restricted stock units.

Summary

• Jay M. Short, PhD, the Chief Executive Officer, Director, and 10% owner of BioAtla, Inc. (BCAB), reported a transaction on May 31, 2025.
• The transaction involved the disposition of 6,347 shares of common stock at a price of $0.409 per share.
• This disposition was not a sale by Dr. Short but rather shares withheld by BioAtla, Inc. to satisfy income tax and withholding obligations associated with the vesting and net settlement of previously granted restricted stock units (RSUs).
• Following this transaction, Dr. Short directly beneficially owns 2,250,025 shares of common stock.
• Additionally, Dr. Short indirectly beneficially owns shares through various entities: 793,547 shares by spouse, 258,727 shares by Carolyn Short 2020 Irrevocable Gift Trust, 258,727 shares by Jay Short 2020 Irrevocable Gift Trust, 302,324 shares by Capia IP, LLC, and 50 shares by Himalaya Parent LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were 'disposed of,' it was for tax withholding related to RSU vesting, indicating that equity compensation is maturing for the CEO, which is generally a positive sign for executive retention and alignment with shareholder interests. It's not a discretionary sale indicating a lack of confidence.

Positives

• The transaction indicates the vesting of previously granted restricted stock units (RSUs), which is a positive sign of equity compensation maturing for the CEO.

Negatives

• The withholding of shares for tax purposes reduces the direct shareholding of the CEO, though it is a standard procedure for RSU vesting.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically related to equity compensation. It does not provide broader industry context or trends for the biotechnology sector, but rather details a specific event for BioAtla's CEO.

Stakeholder Impact

• Shareholders: The transaction is a routine tax-related withholding, not a discretionary sale, which might be viewed neutrally or slightly positively as it indicates the vesting of executive equity compensation.
• Employees: The RSU vesting and tax withholding process is a standard practice for equity compensation, which can be seen as a positive for employee retention and motivation if similar schemes are in place.

Key Dates

Recommendation

Keywords

BioAtla, BCAB, SEC Form 4, Insider Transaction, Jay M. Short, Restricted Stock Units, RSU Vesting, Share Withholding, CEO, Director, 10% Owner, Equity Compensation